ArticleSe pu = Chinese journal of chromatography2026
[Establishment and international comparison of reference methods for glycated hemoglobin].
Article in Se pu = Chinese journal of chromatography, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To promote the standardization and harmonization of glycated hemoglobin A1c (HbA1c) testing results in medical laboratories across Beijing, we established a reference method for HbA1c. This method participated in the International Comparison Program for HbA1c Reference Laboratories organized by the European Reference Laboratory Network for HbA1c to validate its accuracy. The experimental samples consisted of HbA1c network reference laboratory proficiency testing samples imported annually from the Netherlands, including six calibrators (A-F), ten intercomparison samples, several quality control materials, and additional auxiliary samples with International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)-assigned values. The pre-treatment process involved digesting samples with protein endopeptidase Glu-C. The experimental samples were removed from the -80 ℃ freezer and allowed to reach room temperature. Subsequently, 50 μL of Glu-C (mass concentration: 200 μg/mL) was added to each sample vial at a ratio of total hemoglobin to enzyme of 1 mg∶0.01 mg. The volume was then adjusted to a final volume of 500 μL with ammonium acetate solution (50 mmol/L, pH 4.3). After thorough mixing, the samples were incubated at 37 ℃ for 18-20 h. Using mobile phases of methanol and 0.1% formic acid aqueous solution under gradient elution conditions, the detection of HbA1c in international samples was performed via high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). A gradient elution mode was employed for liquid chromatography separation using a Shimadzu C18 column (50 mm×3 mm, 2.2 μm). The injector temperature was maintained at 4-8 ℃, with a column temperature of 30 ℃. The flow rate was kept constant at 0.6 mL/min, with an injection volume of 5 μL and a total run time of 8 min. The MS detection was performed using electrospray ionization (ESI) in positive ion mode with multiple reaction monitoring (MRM). The monitored ion pairs for the precursor and product ions of non-glycated and glycated N-terminal hexapeptides are
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.